Evidence map›Paper›PMID 26166762›Full record

ArticleCellular & molecular immunology2015

Analysis of CD8+ Treg cells in patients with ovarian cancer: a possible mechanism for immune impairment.

Shuping Zhang, Xing Ke, Suyun Zeng, Meng Wu, Jianfang Lou, Lei Wu, Peijun Huang, Lei Huang, Fang Wang, Shiyang Pan

Open access · hybridAbstract read
In one paragraph

Article in Cellular & molecular immunology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
58citing papers in PubMed, 1 pooled it
4.4field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

58 citing papers in PubMed, 1 synthesis or guideline pooled it, 93 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. Circulating CD4Medicina (Kaunas, Lithuania) · 2023
    Article
  17. Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Shuping ZhangDepartment of Laboratory Medicine, the First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Xing KeDepartment of Laboratory Medicine, the First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Suyun ZengDepartment of Obstetrics and Gynecology, Southwest Hospital, Third Military Medical University, Chongqing, China.
Meng WuDepartment of Laboratory Medicine, the First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Jianfang LouDepartment of Laboratory Medicine, the First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Lei WuDepartment of Laboratory Medicine, the First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Peijun HuangDepartment of Laboratory Medicine, the First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Lei HuangDepartment of Laboratory Medicine, the First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Fang WangDepartment of Laboratory Medicine, the First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Shiyang PanDepartment of Laboratory Medicine, the First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Nanjing Medical University · CNJiangsu Province Hospital · CNSouthwest Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Regulatory T (Treg) cells may participate in mediating a suppressive microenvironment that blunts successful anti-tumor immunotherapy. Recent studies show that CD8(+) Treg cells might impede effective immune responses to established tumors. However, there is limited research regarding CD8(+) Treg cells in ovarian cancer (OC) patients. Here, we investigated CD8(+) Treg cells in OC patients and their in vitro induction. The immunohistochemistry of tumor-infiltrating lymphocytes revealed a significant correlation between the intratumoral CD8(+) T cells and the forkhead box p3 (Foxp3)(+) cells in the intraepithelial and stromal areas of advanced OC tissues. We examined the expression of Treg markers in CD8(+) T cells from the peripheral blood and fresh tumor tissues of OC patients using flow cytometry. Our results indicated an increase in the CD8(+) Treg cell subsets of OC patients compared with those in patients with benign ovarian tumors and healthy controls, including an increased expression of CD25, cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), and Foxp3 and decreased CD28 expression. To demonstrate whether the tumor microenvironment could convert CD8(+) effector T cells into suppressor cells, we used an in vitro transwell culturing system. Compared with the CD8(+) T cells cultured alone, the CD8(+) Treg cells induced in vitro by coculture with SK-OV-3/A2780 showed increased CTLA-4 and Foxp3 expression and decreased CD28 expression. In addition, the in vitro-induced CD8(+) Treg cells inhibited naı¨ve CD4(+) T-cell proliferation, which was partially mediated through TGF-β1 and IFN-γ. Our study suggests that CD8(+) Treg cells were increased in OC patients and could be induced in vitro, which may be the way that tumors limit antitumor immunity and evade immune surveillance.

Indexed as

Biomarkers, TumorCase-Control StudiesCD8-Positive T-LymphocytesCell DifferentiationCell Line, TumorCell ProliferationCoculture TechniquesCytokinesFemaleForkhead Transcription FactorsHumansMiddle AgedOvarian NeoplasmsPhenotypeT-Lymphocytes, RegulatoryTransforming Growth Factor beta1Biomarkers, TumorCytokinesForkhead Transcription FactorsFOXP3 protein, humanTransforming Growth Factor beta1

Identifiers

PMID26166762
PMCPMC4579658
OpenAlexW880668976

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.